Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
Want to see ABVX full AI Analyst Report?
Top Page
Abivax SA Sponsored ADR
(NASDAQ:ABVX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$112.00
▼(-6.79% Downside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by weak operating fundamentals (zero revenue in 2025, widening losses, and heavy cash burn). Technicals also lean bearish with the price below key moving averages and negative MACD. The main stabilizer is the improved balance sheet with low leverage and a larger equity base.
Positive Factors
Low leverage and stronger balance sheet
A de‑levered capital structure and materially larger equity base reduce refinancing and solvency risk, giving management time and optionality to progress clinical programs. Low debt supports strategic flexibility for R&D spending or partnerships over the next 2–3 years without immediate leverage constraints.
Negative Factors
Zero revenue with widening losses and high cash burn
No recurring revenue, deepening net losses and sustained negative operating cash flow create persistent value erosion risk. Over months, this pressure can force dilution if pivotal readouts slip, and continued negative free cash flow reduces flexibility to invest or pursue strategic alternatives without further financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and stronger balance sheet
A de‑levered capital structure and materially larger equity base reduce refinancing and solvency risk, giving management time and optionality to progress clinical programs. Low debt supports strategic flexibility for R&D spending or partnerships over the next 2–3 years without immediate leverage constraints.
Read all positive factors
Abivax SA Sponsored ADR (ABVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.92B
Dividend YieldN/A
Average Volume (3M)1.00M
Price to Earnings (P/E)―
Beta (1Y)2.41
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees69
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.22
Shares Outstanding79,291,190
10 Day Avg. Volume748,251
30 Day Avg. Volume1,003,928
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.97K
Enterprise Value/Ebitda-29.95
Forecast
1Y Price Target
$152.25Price Target Upside26.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$3.64M
Abivax SA Sponsored ADR Business Overview & Revenue Model
Company Description
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative ...
How the Company Makes Money
null...
Abivax SA Sponsored ADR Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 10.79M | 4.62M | 4.58M | 37.00K |
| Gross Profit | -1.03M | 10.79M | 4.57M | 4.47M | -119.00K |
| EBITDA | -239.70M | -171.88M | -133.21M | -53.31M | -38.59M |
| Net Income | -322.84M | -176.24M | -147.74M | -60.74M | -42.45M |
Balance Sheet | |||||
| Total Assets | 584.09M | 205.23M | 327.06M | 75.54M | 109.23M |
| Cash, Cash Equivalents and Short-Term Investments | 530.16M | 144.22M | 260.99M | 26.95M | 60.70M |
| Total Debt | 32.08M | 97.36M | 58.04M | 39.16M | 51.65M |
| Total Liabilities | 129.08M | 164.64M | 131.05M | 68.36M | 83.30M |
| Stockholders Equity | 455.01M | 40.58M | 196.01M | 7.19M | 25.93M |
Cash Flow | |||||
| Free Cash Flow | -155.83M | -154.72M | -100.28M | -54.26M | -47.30M |
| Operating Cash Flow | -155.69M | -154.07M | -100.01M | -53.94M | -45.66M |
| Investing Cash Flow | -13.18M | 15.76M | -10.49M | -12.03M | -1.46M |
| Financing Cash Flow | 531.94M | 28.21M | 340.57M | 32.21M | 78.51M |
Abivax SA Sponsored ADR Technical Analysis
Positive
120.16
Price Trends
118.80
Positive
120.36
Negative
97.84
Positive
Market Momentum
1.59
Negative
51.61
Neutral
53.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVX, the sentiment is Positive. The current price of 120.16 is above the 20-day moving average (MA) of 116.64, above the 50-day MA of 118.80, and above the 200-day MA of 97.84, indicating a bullish trend. The MACD of 1.59 indicates Negative momentum. The RSI at 51.61 is Neutral, neither overbought nor oversold. The STOCH value of 53.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABVX.
Abivax SA Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $4.42B | -32.35 | -29.22% | ― | 64.66% | -66.81% | |
58 Neutral | $8.22B | -17.19 | -42.07% | ― | ― | -49.51% | |
54 Neutral | $230.87M | -3.29 | -36.99% | ― | ― | ― | |
52 Neutral | $5.85B | -35.39 | -179.05% | ― | 45.83% | 28.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $8.04B | -9.72 | 172.91% | ― | 376.56% | -23.80% | |
46 Neutral | $8.92B | -24.72 | -165.19% | ― | ― | ― |
* Healthcare Sector Average
ABVX
Abivax SA Sponsored ADR
111.90
104.64
1441.32%
CYTK
Cytokinetics
61.60
20.38
49.44%
RYTM
Rhythm Pharmaceuticals
85.20
20.79
32.28%
LEGN
Legend Biotech
23.65
-11.05
-31.84%
RNA
Atrium Therapeutics, Inc.
12.90
-1.85
-12.54%
NUVL
Nuvalent
104.04
28.84
38.35%
Abivax SA Sponsored ADR Corporate Events
Abivax Publishes Preparatory Documents for May 11, 2026 General Meeting
Apr 20, 2026
Abivax SA, a clinical-stage biotechnology company specializing in immune-regulating therapies for chronic inflammatory diseases, is advancing obefazimod (ABX464) through Phase 3 trials in moderately to severely active ulcerative colitis. The compa...
Abivax Posts 2025 Results, Confirms Phase 3 Ulcerative Colitis Timeline and Expands Leadership Team
Mar 23, 2026
Abivax reported its audited full-year 2025 financial results on March 23, 2026, highlighting a July 28, 2025 U.S. offering that raised about €597.2 million and a year-end cash, cash equivalents and short-term investment balance of €530...
Abivax Unveils Anti-Fibrotic and Phase 3 Safety Data for Obefazimod in IBD at ECCO 2026
Feb 23, 2026
On February 21, 2026, Abivax presented new preclinical and clinical data on its lead candidate obefazimod at the European Crohn’s and Colitis Organization’s 21st Annual Congress, highlighting the first evidence of anti-fibrotic activit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.